Britain and America have secured a major trade agreement that will maintain no duties on British medicine exports being sold in the US market.
The Terms of the Deal
Under the terms of the agreement, the UK has committed to raise spending on medicines through the National Health Service (NHS). This commitment ensures that duties on these crucial goods will remain at zero for a period of the next three years.
This development follows earlier warnings to hike import taxes on patented pharmaceutical products, with increases discussed reaching double the cost.
"This deal with the United Kingdom strengthens the international landscape for new treatments and establishes much-needed fairness to U.S.–U.K. medicine commerce," an announcement noted.
Trade Impact
Medicines constitute one of the the United Kingdom's biggest export categories to the US, which is clearly the largest destination for major companies like GSK and AstraZeneca.
Export figures reveal that in the one-year period leading up to September, the UK shipped drugs totaling billions to the US. This amount represented nearly one-fifth of British export trade in that span.
"This agreement secures jobs, boosts capital expenditure and paves the way for the UK to establish itself as a international leader for biotech and pharma," a minister stated.
Specific UK Commitments
The deal entails several specific commitments from the British government:
- Higher Cost Ceiling: The UK will raise the price threshold at which it judges new treatments to be prohibitively costly by a quarter.
- Higher Drug Budget: There is a goal to double overall public funding on drugs from 0.3% of Gross Domestic Product to 0.6% over the following ten-year period.
- Rebate Cap: The percentage drug companies must refund to the NHS to prevent overspending will be restricted at 15%. Last year, repayments topped 20%.
Recent Tensions
The pact follows a ongoing dispute between the sector and the ministers over medicine costs and NHS adoption.
These tensions were intensified by assertions that US customers were paying several times more for the identical medicines than consumers in the UK and Europe.
Over the last 18 months, several significant drug company projects in the UK have been delayed or abandoned, while substantial funding commitments have been pledged toward projects in the United States.
One official publicly accepted that the NHS needed to invest a greater share on drugs, noting that its expenditure on drugs had declined as a share of its total funding over the previous ten-year period.
